Patent classifications
C12N2310/17
Nucleic acid vaccination using neo-epitope encoding constructs
Products and methods for DNA vaccination targeting cancer. A method for anti-cancer vaccination using a plasmid-based vaccine comprising regions encoding neo-epitopes.
COMPOSITIONS FOR INTRATUMORAL ADMINISTRATION AND RELATED METHODS
The present invention relates to cancer treatment strategies comprising specific combinations of compounds or compositions that are administered intratumorally and can exert both local and distant anti-tumor effects. Preferred compounds and compositions to be combined for the intratumoral administration include a STING agonist and a TLR3 agonist. The disclosed combinations and related pharmaceutical compositions are additionally useful for inclusion in other cancer therapies such as radiotherapy or antibody-based immunotherapies.
IMMUNE INDUCER CONTAINING POLYNUCLEOTIDE-PEPTIDE CONJUGATE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
The present invention provides an immunity-inducing agent comprising a polynucleotide-peptide conjugate or a pharmaceutically acceptable salt thereof as an active component, wherein the polynucleotide-peptide conjugate consists of: a single-chain polynucleotide or polynucleotide derivative comprising a CpG motif; a peptide; and a spacer which is covalently bonded at one end thereof to the polynucleotide or polynucleotide derivative and covalently bonded at the other end thereof to the peptide, wherein the peptide is a peptide modified by substituting one or more contiguous amino acids at the N-terminus of an MHC-binding peptide with an amino acid having a reactive functional group which allows for the formation of a covalent bond with the spacer, wherein the one or more contiguous amino acids contain no anchor residues for MHC binding.
OXIDIZED TUMOR CELL LYSATES ENCAPSULATED IN LIPOSOMAL SPHERICAL NUCLEIC ACIDS AS POTENT CANCER IMMUNOTHERAPEUTICS
The disclosure is generally related to nanoparticles have an oxidized tumor cell lysate encapsulated therein and oligonucleotides on the surface thereof. Methods of making and using the nanoparticles are also provided herein.
NON-AGGREGATING IMMUNOSTIMULATORY OLIGONUCLEOTIDES
Provided are non-aggregating immunostimulatory oligonucleotides. The present invention also provides a delivery agent for an immunostimulatory-oligonucleotide nucleic acid medicine, said delivery agent including a nucleic acid that contains a phosphorothioated nucleotide. According to another aspect, the present invention further provides an oligonucleotide including a bioactive core, and a nucleic acid that contains a phosphorothioated nucleotide. The present invention yet further provides an immunostimulator including the bioactive core of a type A/D, type B/K, or type C immunostimulatory oligonucleotide.
BISPECIFIC PERSONALIZED APTAMERS
Provided herein are bispecific personalized aptamers that induce the cell death of cancer cells and methods of use thereof.
Method for improving immunity in shrimps
The invention discloses a method for improving immunity in shrimps, by administering a double-stranded RNA specific to tyrosine hydroxylase to a shrimp body to improve immunity of the shrimp body, wherein the double-stranded RNA is administered to the shrimp body by injection into the ventral sinus of the cephalothorax of the shrimp body.
IMMUNOMODULATION BY CONTROLLING ELR+ PROINFLAMMATORY CHEMOKINE LEVELS WITH THE LONG NON-CODING RNA UMLILO
The present invention relates to methods for modulating the production of ELR+ proinflammatory chemokines in a subject or a cell using either UMLILO IncRNA inhibitors to decrease production of ELR+ proinflammatory cytokines or using UMLILO IncRNA's to increase the production of ELR+ proinflammatory cytokines. The invention also provides for the use of UMLILO IncRNA inhibitors or UMLILO IncRNA's to modulate the expression of ERL+ proinflammatory cytokines.
COMBINATION THERAPY WITH MODIFIED PBMCS AND AN IMMUNOCONJUGATE
The present application provides methods for stimulating an immune response in an individual comprising administering a composition of nucleated cells (e.g., PBMCs) comprising an intracellular exogenous antigen in conjunction with administering an immunoconjugate comprising a variant IL-2 polypeptide and a second polypeptide. The variant IL-2 polypeptide exhibits reduced affinity to the α-subunit of the IL-2 receptor. The second polypeptide targets a tumor cell or a T cell.
IMMUNOSTIMULATORY COMPOSITIONS
The present disclosure relates to immunostimulatory compositions that are effective in eliciting immune responses in avian species. More specifically, these immunostimulatory compositions comprise an immunomodulator composition and an immunostimulatory oligonucleotide that when administered